Skip to main content

Fiscal Wizard · Single-issue tearsheet

SEPN / Jun 21, 2026 Run #7407

SEPN

Septerna, Inc.

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Composite verdict

A 85.8 / 100
Bullish setup · Trend Following 15 drivers · 3 gates blocking
  • Rate of Change
  • 52-Week Proximity
  • Trendline Break
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 10th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 18 signals0% Bear
Momentum Bullish 99Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -96%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Strong

71.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 100
P/S Ratio 25
Free Cash Flow Yield 82
EV/Sales 25

Technicals Bullish

100.0 / 100

Bullish setup leads (Rate of Change, 52-Week Proximity, Trendline Break); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 93
52-Week Proximity 89
Trendline Break 89

Risk Gates

3 blocking 6 caution

3 guards active, 21 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for SEPN.